Myris Therapeutics, Inc. — SEC Form D Filing
Myris Therapeutics, Inc. filed an SEC Form D on October 14, 2026, reporting $500K raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 14, 2026
- Amount reported
- $500K
- Round stage
- Pre-Seed
- Industry
- Biotechnology
- Website
- https://www.myristx.com/
What the company does
Securities: Convertible Promissory Notes. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Existing antibody drug conjugates (ADCs) have limitations in payload choice, potentially restricting their effectiveness in targeting various oncogenic pathways.
Solution
Myris Therapeutics is developing next-generation antibody drug conjugates (ADCs) using polymer chemistry to achieve ultra-high Drug-to-Antibody Ratio (DAR), which expands the range of possible therapeutic payloads for targeted cancer therapy.
Why now
Advances in polymer chemistry and a deeper understanding of targeted therapy mechanisms, particularly in oncology, allow for the development of more effective and versatile drug delivery systems like ultra-high DAR ADCs.
Verdict
This cleared because the team articulated a compelling technical advancement in a known high-value therapeutic modality, not because of a fully fleshed out commercialization path. Investors were implicitly betting on the ability to demonstrate a significant *in vivo* efficacy advantage over current ADC platforms, assuming regulatory bodies would eventually favor improved DAR. The limited upside stemmed from the early stage, where the half-million dollar round primarily funded further proof-of-concept, rather than early clinical milestones.
Source: SEC EDGAR Form D filing